

Accepted Manuscript

Mechanisms of vascular dysfunction in COPD and effects of a novel soluble epoxide hydrolase inhibitor in smokers

Lucy Yang, MBChB, Joseph Cheriyan, FRCP, David D. Gutterman, MD, Ruth J. Mayer, PhD, Zsuzsanna Ament, PhD, Jules L. Griffin, PhD, Aili L. Lazaar, MD, David E. Newby, FRCP, Ruth Tal-Singer, PhD, Ian B. Wilkinson, FRCP

PII: S0012-3692(16)62392-9

DOI: [10.1016/j.chest.2016.10.058](https://doi.org/10.1016/j.chest.2016.10.058)

Reference: CHEST 817

To appear in: *CHEST*


Received Date: 21 July 2016

Revised Date: 4 October 2016

Accepted Date: 28 October 2016

Please cite this article as: Yang L, Cheriyan J, Gutterman DD, Mayer RJ, Ament Z, Griffin JL, Lazaar AL, Newby DE, Tal-Singer R, Wilkinson IB, Mechanisms of vascular dysfunction in COPD and effects of a novel soluble epoxide hydrolase inhibitor in smokers, *CHEST* (2016), doi: 10.1016/j.chest.2016.10.058.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Word count: Text 2430 words, Abstract 246 words.

Full Title: Mechanisms of vascular dysfunction in COPD and effects of a novel soluble epoxide hydrolase inhibitor in smokers

Running head: Vascular dysfunction in COPD and sEH inhibition in smokers

Lucy Yang MBChB^{*1}, Joseph Cheriyan FRCP^{*1,2,3}, David D. Gutterman MD⁴, Ruth J. Mayer PhD⁵, Zsuzsanna Ament PhD⁶, Jules L. Griffin PhD⁶, Aili L. Lazaar MD⁵, David E. Newby FRCP⁷, Ruth Tal-Singer PhD⁵, Ian B. Wilkinson FRCP^{1,2}

1. Experimental Medicine & Immunotherapeutics (EMIT), University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
2. Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
3. Clinical Unit Cambridge, GSK R&D, Cambridge CB2 0GG, UK.
4. Department of Medicine, Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA.
5. GSK R&D, King of Prussia, PA, USA.
6. MCR Human Nutrition Research, Elsie Widdowson Laboratory, 120 Fulbourn Road, Cambridge CB1 9NL & Department of Biochemistry, Tennis Court Road, University of Cambridge, Cambridge CB2 1GA.
7. British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, EH16 4SB, UK.

* joint first authors.

Correspondence:

Dr. Joseph Cheriyan, EMIT, University of Cambridge, Addenbrooke's Hospital, UK. Email: jc403@medschl.cam.ac.uk

Download English Version:

<https://daneshyari.com/en/article/5600995>

Download Persian Version:

<https://daneshyari.com/article/5600995>

[Daneshyari.com](https://daneshyari.com)